Ameliorative effect of tranexamic acid on physiological skin aging and its sex difference in mice.


Journal

Archives of dermatological research
ISSN: 1432-069X
Titre abrégé: Arch Dermatol Res
Pays: Germany
ID NLM: 8000462

Informations de publication

Date de publication:
Sep 2019
Historique:
received: 07 01 2019
accepted: 24 05 2019
revised: 17 04 2019
pubmed: 31 5 2019
medline: 15 2 2020
entrez: 1 6 2019
Statut: ppublish

Résumé

An effective method to protect the skin from natural aging is unknown. Therefore, in this study, we examined the ameliorative effects of tranexamic acid on natural skin aging. In addition, we examined the sex difference in the effect exhibited by tranexamic acid. We bred hairless mice without ultraviolet ray irradiation and physical stress for 2 years. During the study period, mice were orally administered tranexamic acid (12 mg/kg/day) three times per week. Development of signs of skin aging was found to be ameliorated by tranexamic acid. Furthermore, synthetic inhibition of plasmin was observed following tranexamic acid treatment. The synthetic reinforcement of hyaluronic acid by an increase in the number of epidermal cells and the degradative inhibition of extracellular matrix (ECM) by matrix metalloproteinase (MMP) suppression were observed. These results indicate that natural skin aging was ameliorated by tranexamic acid via the regulation of the plasmin/TGF-β/epidermal cells/hyaluronic acid and plasmin/MMPs/ECM signal transmission pathways. Taken together, sex difference was observed for the ameliorative effect of tranexamic acid on skin aging, with a stronger effect observed in females than in males. More importantly, we found that the synthesis of hyaluronic acid was stronger in female mice than in male mice.

Identifiants

pubmed: 31147768
doi: 10.1007/s00403-019-01938-5
pii: 10.1007/s00403-019-01938-5
doi:

Substances chimiques

Antifibrinolytic Agents 0
Sex Hormone-Binding Globulin 0
Transforming Growth Factor beta 0
Tranexamic Acid 6T84R30KC1
Hyaluronic Acid 9004-61-9
Fibrinolysin EC 3.4.21.7

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

545-553

Subventions

Organisme : Japan Society for the Promotion of Science (JP)
ID : 18K11085

Auteurs

Keiichi Hiramoto (K)

Department of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagakicho, Suzuka, Mie, 513-8670, Japan. hiramoto@suzuka-u.ac.jp.

Yurika Yamate (Y)

Department of Pharmaceutical Sciences, Suzuka University of Medical Science, 3500-3 Minamitamagakicho, Suzuka, Mie, 513-8670, Japan.

Daijiro Sugiyama (D)

R&D Department, Daiichi Sankyo Healthcare Co., LTD., 3-14-10 Nihonbashi, Chuo-ku, Tokyo, 103-8234, Japan.

Kazunari Matsuda (K)

R&D Department, Daiichi Sankyo Healthcare Co., LTD., 3-14-10 Nihonbashi, Chuo-ku, Tokyo, 103-8234, Japan.

Yasutaka Iizuka (Y)

R&D Department, Daiichi Sankyo Healthcare Co., LTD., 3-14-10 Nihonbashi, Chuo-ku, Tokyo, 103-8234, Japan.

Tomohiko Yamaguchi (T)

R&D Department, Daiichi Sankyo Healthcare Co., LTD., 3-14-10 Nihonbashi, Chuo-ku, Tokyo, 103-8234, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH